Prostate cancer is the most frequently diagnosed cancer in men in 112 countries. A vast majority of patients diagnosed with CRPC already present with metastases at the time of diagnosis. Those with metastatic prostate cancer have an estimated 30% chance of surviving five years.
Novartis’ open-label, multi-centre, 1:1 randomised phase 3 PSMAfore trial with Pluvicto – a prostate-specific membrane antigen – evaluated 469 participants and met the primary endpoint of radiographic progression-free survival (rPFS) in PSMA-positive mCRPC patients who have been treated with androgen-receptor pathway inhibitor (ARPI) therapy, compared to a change in ARPI.
